ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)
China · Delayed Price · Currency is CNY 10.68
+0.11 (1.04%)
At close: Feb 4, 2026
SHE:300254 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Net Income | 20.36 | 42.19 | 25.2 | -118.52 | -91.44 | -262.37 |
Depreciation & Amortization | 57.62 | 57.62 | 58.53 | 64.79 | 66.93 | 64.82 |
Other Amortization | 1.65 | 1.65 | 0.85 | 0.75 | 0.74 | 0.87 |
Loss (Gain) From Sale of Assets | -7.51 | -7.51 | -18.8 | -0.69 | 0.37 | -0.01 |
Asset Writedown & Restructuring Costs | 5.67 | 5.67 | 5.51 | 48.4 | 31.68 | 76.65 |
Loss (Gain) From Sale of Investments | -4.54 | -4.54 | -20.88 | 3.43 | -13.64 | 0.22 |
Provision & Write-off of Bad Debts | 5.78 | 5.78 | -0.43 | 0.71 | -5.32 | 5.1 |
Other Operating Activities | 86.81 | 52.64 | 56.12 | 68.93 | 73.92 | 40.75 |
Change in Accounts Receivable | -71.14 | -71.14 | -5.35 | -120.83 | 119.48 | 44.69 |
Change in Inventory | -28.39 | -28.39 | -20.61 | 3.81 | 6.31 | 6.36 |
Change in Accounts Payable | 13.4 | 13.4 | -40.02 | 123.41 | -91.56 | 23.3 |
Change in Other Net Operating Assets | 13.48 | 13.48 | - | - | - | - |
Operating Cash Flow | 83.28 | 70.94 | 37.81 | 74.88 | 96.92 | -20.88 |
Operating Cash Flow Growth | -7.52% | 87.60% | -49.50% | -22.75% | - | - |
Capital Expenditures | -19.08 | -51.5 | -33.92 | -26.78 | -36.93 | -31.46 |
Sale of Property, Plant & Equipment | 0.27 | 0.21 | 100.83 | 2.12 | 6.42 | 3.16 |
Cash Acquisitions | - | - | - | - | - | 4.99 |
Divestitures | - | 1.63 | - | - | -0.27 | - |
Investment in Securities | -263.13 | -202.84 | 5.19 | 1.47 | 5.57 | 16.1 |
Other Investing Activities | 4.23 | 4.23 | - | - | - | 1.79 |
Investing Cash Flow | -277.71 | -248.27 | 72.1 | -23.2 | -25.21 | -5.41 |
Short-Term Debt Issued | - | 1.8 | - | - | - | - |
Long-Term Debt Issued | - | 321.62 | 115.75 | 271.6 | 100.9 | 224.08 |
Total Debt Issued | 359.6 | 323.42 | 115.75 | 271.6 | 100.9 | 224.08 |
Short-Term Debt Repaid | - | -1.8 | - | - | - | - |
Long-Term Debt Repaid | - | -144.7 | -138.74 | -223.42 | -218.32 | -271.4 |
Total Debt Repaid | -292.01 | -146.5 | -138.74 | -223.42 | -218.32 | -271.4 |
Net Debt Issued (Repaid) | 67.59 | 176.93 | -22.99 | 48.18 | -117.42 | -47.32 |
Issuance of Common Stock | 43.96 | 33.35 | - | 105.25 | - | 140 |
Repurchase of Common Stock | -1.66 | -1.66 | -203.24 | - | - | - |
Common Dividends Paid | -18.48 | -12.32 | -13.31 | -11.9 | -14.67 | -20.82 |
Other Financing Activities | 55.52 | -1.45 | -2.23 | -28.96 | -20.21 | -8.52 |
Financing Cash Flow | 146.93 | 194.84 | -241.77 | 112.56 | -152.3 | 63.33 |
Foreign Exchange Rate Adjustments | - | - | - | - | - | 0.01 |
Net Cash Flow | -47.5 | 17.51 | -131.85 | 164.24 | -80.58 | 37.05 |
Free Cash Flow | 64.2 | 19.44 | 3.9 | 48.09 | 59.99 | -52.34 |
Free Cash Flow Growth | 401.11% | 398.72% | -91.90% | -19.84% | - | - |
Free Cash Flow Margin | 7.56% | 2.30% | 0.49% | 5.80% | 6.45% | -6.17% |
Free Cash Flow Per Share | 0.26 | 0.08 | 0.02 | 0.20 | 0.26 | -0.24 |
Cash Income Tax Paid | 434.46 | 413.61 | 424.75 | 89.17 | 89.28 | 89.18 |
Levered Free Cash Flow | -205.98 | 52.96 | -161.38 | 316.58 | 23.16 | 16.84 |
Unlevered Free Cash Flow | -192.06 | 63.57 | -140.65 | 345.37 | 53.89 | 51.02 |
Change in Working Capital | -82.56 | -82.56 | -68.28 | 7.07 | 33.67 | 53.09 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.